Standard treatment of patients with advanced ALK-positive NSCLC has recently shifted to sequential treatment with crizotinib, followed by increasingly potent second-generation ALK TKIs, including alectinib, brigatinib, and ceritinib [4–6]. Here, ALK is linked to non-small cell lung carcinoma.